Tenaya Therapeutics, Inc. (TNYA)

In July 2025, Tenaya's stock climbed 4.2% following positive safety endorsements for its TN-201 and TN-401 clinical trials. In August 2025, the company reported a net loss of $23.3 million for Q2 2025, and the stock declined 1.69%. In November 2025, the FDA placed a clinical hold on the mid-stage trial for TN-201, leading to a 16% drop in the stock price, despite interim safety and efficacy data being presented. In December 2025, the FDA lifted the clinical hold on the TN-201 trial, and encouraging interim Phase 1b/2 data for TN-401 was released, but the stock was down 39.7% due to a US$60,000,000 composite units offering and a decreased price target. In January 2026, Tenaya announced its 2026 strategic priorities and the resignation of David Goeddel from the Board, with the share price at $0.77, a 47.28% decline over the year.

As a clinical-stage biotechnology company without commercialized products, Tenaya Therapeutics does not have demand seasonality. Its financial model is focused on research and development, funded by capital sources rather than product sales.

Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing curative therapies for heart disease through gene therapy, cellular regeneration, and precision medicine. The company does not generate revenue from product sales, relying on equity financing, strategic collaborations, and grants. Its pipeline includes TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM) in Phase 2 trials, TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) in Phase 1 trials, and TN-301, a small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction (HFpEF) in Phase 1 trials. Tenaya is also developing gene therapy for dilated cardiomyopathy and a reprogramming program for heart failure due to prior myocardial infarction.

Tenaya Therapeutics is headquartered in South San Francisco, California, USA, with operations primarily focused within the United States. There is no specific information available regarding its international operations or a disclosed geographic breakdown of revenue, indicating a limited or non-disclosed international footprint at this stage.

Tenaya Therapeutics' brand reputation has been influenced by the progress and setbacks in its clinical trials. The company's mission and focus on patients and scientific excellence contribute to a positive image. Positive safety reviews have bolstered its reputation, while the FDA's clinical hold on the TN-201 trial temporarily impacted its standing, though the subsequent lifting of the hold helped to mitigate this.

Tenaya Therapeutics is owned by venture capital firms, institutional asset managers, company insiders, and the public. Insider ownership is reported to be around 71.20% or 48.65%, while institutional ownership ranges from approximately 8.39% to 90.54%. Major institutional shareholders include Column Group LLC, Vanguard Group Inc, Millennium Management LLC, BlackRock, Inc., VTSMX, VEXMX, Renaissance Technologies LLC, Geode Capital Management, LLC, Euclidean Capital LLC and Alphabet Inc.